How to take Tivozanib

Tivozanib is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) that is relapsed or refractory after two or more prior systemic therapies. The recommended dose of tivozanib is 1.34 mg orally once daily for 21 days, followed by 7 days off treatment in a 28-day cycle, with treatment continued until disease progression or unacceptable toxicity.

Tivozanib helps stop the disease from getting worse, according to a major study of517 people with advanced renal cell carcinoma who had come back or spread to other parts of the body. In this study, patients who took tivozanib lived longer without their disease worsening (12 months) than those who took another approved drug, sorafenib (9 months). If the patient develops adverse reactions after taking tivozanib, the dose may need to be adjusted. During the 28-day treatment cycle, the dose of tivozanib is reduced to 0.89 mg, treated for 21 days, and then discontinued for 7 days. Medical treatment of adverse events such as diarrhea, nausea, or vomiting is required before dose interruption or reduction. For patients with moderate hepatic impairment, reduce the recommended dose of tivozanib to 0.89 mg orally once daily for 21 days, followed by 7 days off for a 28-day treatment cycle.

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.